Rolvedon neutropenia
Search results
Scope
Date
~
-
Bio & PharmaHanmi's Rolvedon set to post $10 mn in Q4 net sales in US
South Korean drugmaker Hanmi Pharmaceutical Co.’s neutropenia agent, Rolvedon (eflapegrastim-xnst), is forecast to achieve about $10 million i...
Feb 02, 2023 (Gmt+09:00)
-
Bio & PharmaHanmi’s anti-cancer drug Rolontis gets FDA approval; US sale via Spectrum
South Korea’s Hanmi Pharmaceutical Co. said on Tuesday that Rolontis, an anti-cancer drug it has jointly developed with its US partner, has ob...
Sep 13, 2022 (Gmt+09:00)
-
Bio & PharmaKorea Hanmi to launch blockbuster hypertension drug in China
South Korea’s Hanmi Pharmaceutical Co. is set to launch its blockbuster high blood pressure drug Amosartan in China, the world’s largest...
Mar 11, 2022 (Gmt+09:00)
language
1
Latest News
- 1 Seoul appeal: Korean art captivates Indonesia’s affluent connoisseurs
- 2 CJ CheilJedang scraps $3.5 bn green bio sale, shifts gears to expansion
- 3 Trump Jr. meets Korean business chiefs in back-to-back sessions
- 4 Samsung in talks to supply customized HBM4 to Nvidia, Broadcom, Google
- 5 Kookmin Bank raises $700 mn in forex bonds amid strong demand
